Benitec Biopharma (BNTC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Oct, 2026Executive summary
Annual stockholder meeting scheduled for December 3, 2026, online at 1:00 p.m. PT; three proposals are up for a vote.
Voting matters and shareholder proposals
Ballot includes election of three Class I directors, auditor ratification for FY ending June 30, 2027, and an advisory vote on named executive officer compensation.
Board recommends FOR all director nominees and FOR auditor ratification and the advisory compensation proposal.
Board of directors and corporate governance
Class I nominees are Dr. Sharon Mates, Kishen Mehta, and Edward Smith.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Benitec Biopharma
- Three director elections, auditor ratification and say-on-pay headline the 2026 meeting.BNTC
Proxy filing - BB-301 gene therapy showed durable, dose-dependent efficacy and safety in OPMD-related dysphagia.BNTCCorporate presentation
- Biotech seeks up to $200M for gene therapy pipeline, targeting rare diseases with novel ddRNAi tech.BNTCRegistration filing
- BB-301 clinical progress and robust cash reserves highlight a year of operational and financial momentum.BNTCQ4 2026
- BB-301 showed strong interim results and $184.8M cash, narrowing Q3 net loss to $11.9M.BNTCQ3 2026
- Net loss rose to $20.8M, cash at $189M, and BB-301 showed durable efficacy in Cohort 1.BNTCQ2 2026
- BB-301 showed marked clinical benefit in OPMD patients, with robust safety and financial position.BNTCCorporate presentation
- BB-301 achieved 100% responder rate and strong safety in OPMD dysphagia, advancing to pivotal trials.BNTCCorporate presentation
- Gene therapy innovator registers 1.48M shares for resale after $100M in recent offerings.BNTCRegistration Filing